Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.39 |
| ▸ | DPP4 | P27487 | 17/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 14/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6165300 | 1.00 | DPP7 (0.39) | DPP7DPP4DPP8DPP9ALOX15 | |
| SCHEMBL7418737 | 1.00 | DPP7 (0.39) | DPP7DPP4DPP8DPP9ALOX15 | |
| SCHEMBL6175048 | 0.83 | DPP7 (0.56) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL6175043 | 0.83 | DPP7 (0.56) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL7257356 | 0.83 | DPP7 (0.56) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL6175639 | 0.82 | DPP4 (0.35) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL7422812 | 0.82 | DPP4 (0.35) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL6174604 | 0.82 | DPP4 (0.40) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL6174600 | 0.82 | DPP4 (0.40) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL7189181 | 0.82 | DPP4 (0.40) | DPP7DPP4DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070719-A1 | Inhibitors of dipeptidyl peptidase iv | GUILFORD PHARMACEUTICALS | 2005-03-31 | — | — | US | disclosed |
| US-6645995-B2 | Dipeptidyl peptidase-IV (DPP-IV); treating type II diabetes in a human; amino acid amides of 2-cyanopyrrolidine | NOVO NORDISK A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS (DK) | 2002-08-01 | — | — | US | disclosed |
| US-6380398-B2 | COMPOUNDS SUCH AS (S,S)1-(2-AMINO-3,3-DIMETHYL-BUTYRYL)-2,5-DIHYDRO-1H-PYRROLE-2 -CARBONITRILE ADMINISTERED AS ANTIDIABETIC AGENTS; DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | NOVO NORDISK A/S (DK) | 2002-04-30 | — | — | US | disclosed |
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | DPP7 2/4885DPP4 1/4885DPP8 5/4885 |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | DPP7 2/4885DPP4 1/4885DPP8 5/4885 |
| US-20050070719-A1 | Inhibitors of dipeptidyl peptidase iv | DPP4, DPP3, DPP7 | DPP7 3/4885DPP4 1/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.